Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of MXN 460.85 billion. The enterprise value is 502.74 billion.

Market Cap	460.85B
Enterprise Value	502.74B

Important Dates

The next confirmed earnings date is Wednesday, April 29, 2026.

Earnings Date	Apr 29, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.76M
Shares Outstanding	n/a
Shares Change (YoY)	+0.82%
Shares Change (QoQ)	-0.27%
Owned by Insiders (%)	0.20%
Owned by Institutions (%)	96.45%
Float	146.28M

Valuation Ratios

The trailing PE ratio is 19.80 and the forward PE ratio is 11.66.

PE Ratio	19.80
Forward PE	11.66
PS Ratio	2.59
PB Ratio	1.40
P/TBV Ratio	9.89
P/FCF Ratio	12.48
P/OCF Ratio	11.61
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.76, with an EV/FCF ratio of 13.62.

EV / Earnings	21.60
EV / Sales	2.92
EV / EBITDA	7.76
EV / EBIT	10.24
EV / FCF	13.62

Financial Position

The company has a current ratio of 2.68, with a Debt / Equity ratio of 0.36.

Current Ratio	2.68
Quick Ratio	1.70
Debt / Equity	0.36
Debt / EBITDA	1.79
Debt / FCF	3.25
Interest Coverage	10.56

Financial Efficiency

Return on equity (ROE) is 7.39% and return on invested capital (ROIC) is 11.19%.

Return on Equity (ROE)	7.39%
Return on Assets (ROA)	6.14%
Return on Invested Capital (ROIC)	11.19%
Return on Capital Employed (ROCE)	10.82%
Weighted Average Cost of Capital (WACC)	4.77%
Revenue Per Employee	23.74M
Profits Per Employee	3.10M
Employee Count	7,500
Asset Turnover	0.34
Inventory Turnover	0.90

Taxes

In the past 12 months, Biogen has paid 4.75 billion in taxes.

Income Tax	4.75B
Effective Tax Rate	16.94%

Stock Price Statistics

The stock price has increased by +15.10% in the last 52 weeks. The beta is 0.16, so Biogen's price volatility has been lower than the market average.

Beta (5Y)	0.16
52-Week Price Change	+15.10%
50-Day Moving Average	2,840.49
200-Day Moving Average	3,778.15
Relative Strength Index (RSI)	58.22
Average Volume (20 Days)	80

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.57

Income Statement

In the last 12 months, Biogen had revenue of MXN 178.06 billion and earned 23.28 billion in profits. Earnings per share was 158.25.

Revenue	178.06B
Gross Profit	140.57B
Operating Income	50.84B
Pretax Income	28.02B
Net Income	23.28B
EBITDA	64.88B
EBIT	50.84B
Earnings Per Share (EPS)	158.25

Balance Sheet

The company has 68.69 billion in cash and 119.86 billion in debt, giving a net cash position of -43.39 billion.

Cash & Cash Equivalents	68.69B
Total Debt	119.86B
Net Cash	-43.39B
Net Cash Per Share	n/a
Equity (Book Value)	328.68B
Book Value Per Share	2,238.97
Working Capital	101.26B

Cash Flow

In the last 12 months, operating cash flow was 39.69 billion and capital expenditures -2.77 billion, giving a free cash flow of 36.92 billion.

Operating Cash Flow	39.69B
Capital Expenditures	-2.77B
Depreciation & Amortization	13.58B
Net Borrowing	-5.17B
Free Cash Flow	36.92B
FCF Per Share	n/a

Margins

Gross margin is 78.95%, with operating and profit margins of 28.55% and 13.07%.

Gross Margin	78.95%
Operating Margin	28.55%
Pretax Margin	15.74%
Profit Margin	13.07%
EBITDA Margin	36.44%
EBIT Margin	28.55%
FCF Margin	20.73%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.82%
Shareholder Yield	-0.82%
Earnings Yield	5.05%
FCF Yield	8.01%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 2.97 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.97
Piotroski F-Score	6